Number of pay-for-delay deals remains low, says FTC
07-12-2020
Judge gives initial approval to Actavis $20m antitrust deal
15-09-2020
10-12-2020
rafapress / Shutterstock.com
New Jersey-based Tris Pharma has won a ruling blocking Teva-owned Actavis from launching a generic version of attention deficit and hyperactivity disorder (ADHD) drug Quillivant XR (methylphenidate).
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Tris, Actavis, ADHD, generics, Ritalin, methylphenidate, Quillivant XR, Federal Circuit